Dianthus' Monoclonal Antibody On Promising Pathway To Gaining The Upper Hand - Analyst
Portfolio Pulse from Vandana Singh
Raymond James initiated coverage on Dianthus Therapeutics Inc (DNTH) with an Outperform rating and a price target of $24. The company's lead asset, DNTH103, is an antibody designed to target active C1s and is protected by intellectual property rights until 2043. Dianthus is initiating a Phase 2 gMG study with a target product profile that will potentially offer dosing advantages and safety advantages over prevailing comps. Phase 2 data are expected by 2H25.
September 28, 2023 | 7:33 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Dianthus Therapeutics received an Outperform rating from Raymond James, which could boost investor confidence and potentially increase the stock price.
Analyst ratings often influence investor sentiment and can impact a company's stock price. In this case, the Outperform rating from Raymond James could lead to increased investor confidence in Dianthus Therapeutics, potentially driving up the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEUTRAL IMPACT
Dianthus' DNTH103 is expected to be at least as efficacious as AstraZeneca's Soliris/Ultomiris.
The expectation that Dianthus' DNTH103 will match the efficacy of AstraZeneca's Soliris/Ultomiris could potentially impact both companies. However, the direct impact on AstraZeneca's stock price is uncertain.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 50
NEUTRAL IMPACT
Sanofi's approval of Enjaymo, an antibody targeting total C1s for Cold Agglutinin Disease (CAD), has de-risked Dianthus' targeting strategy.
Sanofi's approval of Enjaymo has de-risked Dianthus' targeting strategy. This could potentially benefit both companies, but the direct impact on Sanofi's stock price is uncertain.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 50
NEUTRAL IMPACT
Dianthus' DNTH103 is expected to be at least as efficacious as Ra Pharmaceuticals' Zilucoplan.
The expectation that Dianthus' DNTH103 will match the efficacy of Ra Pharmaceuticals' Zilucoplan could potentially impact both companies. However, the direct impact on Ra Pharmaceuticals' stock price is uncertain.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 50
NEUTRAL IMPACT
Dianthus' DNTH103 is expected to be at least as efficacious as Ra Pharmaceuticals' Zilucoplan.
The expectation that Dianthus' DNTH103 will match the efficacy of Ra Pharmaceuticals' Zilucoplan could potentially impact both companies. However, the direct impact on Ra Pharmaceuticals' stock price is uncertain.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 50